Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...
This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...
Please provide your email address to receive an email when new articles are posted on . Patients who received subcutaneous amivantamab-vmjw every 4 weeks plus lazertinib had similar outcomes as those ...
The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results